Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater by Banaschewski, T et al.
1 
 
PERSPECTIVE ARTICLE 
Methylphenidate for ADHD in children and adolescents: throwing the baby out with 
the bathwater 
 
 
Tobias Banaschewski,1 Jan Buitelaar,2 Celine SL Chui,3 David Coghill,4 Samuele Cortese,5 
Emily Simonoff,6* Ian CK Wong 3,7 on behalf of the European ADHD Guidelines Group 
1Department of Child Adolescent Psychiatry and Psychotherapy, Central Institute of Mental 
Health, Mannheim, Germany 
2Department of Cognitive Neuroscience, Donders Institute of Brain, Cognition and Behavior, 
Radboud University Medical Center, Nijmegen, The Netherlands, and Karakter Child and 
Adolescent Psychiatry University Center, Nijmegen, The Netherlands 
3Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China 
4Departments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health 
Sciences, University of Melbourne, Victoria, Australia 
5Department of Psychology, University of Southampton, Southampton, UK and Clinical and 
Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of 
Southampton, UK 
6Department of Child & Adolescent Psychiatry, King’s College London, Institute of 
Psychiatry Psychology & Neuroscience, London, UK 
7 Research Department of Practice and Policy, UCL School of Pharmacy, London, UK 
 
 
Word count: 1992 
 
2 
 
*Correspondence to:  
Emily Simonoff 
Department of Child and Adolescent Psychiatry 
King’s College London, Institute of Psychiatry, Psychology and Neuroscience 
Box 85, DeCrespigny Park, London SE5 8LF 
Phone (00 44) (0) 207 8848 5313 
Fax (00 44) (0) 207  508 5600 
E-mail: emily.simonoff@kcl.ac.uk 
 
 
3 
 
ABSTRACT 
A recent Cochrane review assessed the efficacy of methylphenidate for attention-
deficit/hyperactivity disorder (ADHD) in children and adolescents. Notwithstanding the 
moderate-to-large effect sizes for ADHD symptom reduction found in the meta-analysis, the 
authors concluded that the quality of the evidence is low and therefore the true magnitude of 
these effects remain uncertain. We identified a number of major concerns with the review, in 
the domains of study inclusion, approaches to quality assessment, and interpretation of data 
relating to serious adverse events as well as of the clinical implications of the reported 
effects. We also found errors in the extraction of data used to estimate the effect size of the 
primary outcome. Considering all the shortcomings, the conclusion in the Cochrane review 
that the status of the evidence is uncertain is misplaced. Professionals, parents and patients 
should refer to previous reviews and existing guidelines, which include methylphenidate as 
one of the safe and efficacious treatment strategies for ADHD.  
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Attention-deficit/hyperactivity disorder (ADHD) is a common disorder commencing 
in childhood and frequently persisting across the lifespan. Current treatment guidelines, 
including those of  the National Institute for Health and Care Excellence (NICE)1, identify 
methylphenidate (MPH) as a first-line treatment for ADHD. Furthermore, previous 
systematic reviews and meta-analyses (e.g.2 3) have reported large effect sizes for the efficacy 
of MPH in the treatment of ADHD, at least in the short term.   
In November 2015, Storebø et al.4 published a Cochrane review on the efficacy and 
tolerability of MPH for the treatment of ADHD in children and adolescents. This review 
challenged the conclusions of previous reviews and guidelines. Whilst the meta-analysis 
found similar effect sizes in relation to efficacy to those previously reported, the authors 
concluded that the magnitude of this effect is uncertain due to the very low quality of the 
evidence. As such, the conclusions of Storebø et al.4 could raise questions about the role of 
MPH as a core component of ADHD treatment. As an international group committed to the 
provision of evidence-based clinical guidance on the management of ADHD, we do not agree 
with the conclusions of Storebø et al.4  Rather, we argue that the Storebø et al. review4 is 
flawed in a number of ways that lead to these incorrect conclusions:  
1. Inappropriate selection of studies for inclusion; 
2. Internal inconsistencies and idiosyncratic procedures in the risk of bias and 
overall study quality assessment; 
3. Misinterpretations of evidence in relation to serious adverse events;  
4. A misunderstanding of the meaning of effect sizes, and their clinical 
implications for individual patients.  
Additionally, there are a number of errors in the calculation of standardized mean differences 
and meta-analytic weights.  
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Inappropriate study inclusion. As per their protocol, Storebø et al.4 aimed to include 
randomized controlled trials (RCTs) comparing MPH with placebo or no intervention, 
allowing co-interventions provided that the compared intervention groups received the co-
intervention similarly. In fact, Storebø et al.4 included three studies, amongst them the large 
MTA study, where there was no placebo/no treatment arm5 6 and/or where MPH was used as 
an add-on intervention5-7, and a study (included only in secondary analyses) that was not 
randomized.8  Removing these studies increases the effect size for the primary outcome of 
teacher-reported ADHD symptom ratings from -0.77 (95% CIs -0.90, -0.64) to -0.83 (95% 
CIs -0.96, - 0.70).  The inclusion of the large MTA study5 has important implications for all 
subgroup analyses of long-term (>6 months) versus short-term MPH administration. Storebø 
et al.4 reported a smaller effect for long-term administration according to teacher (but not 
parent or observer) reports. However, as the MTA is the only study meeting their definition 
of long-term administration these analyses are misleading. We agree with Storebø et al.4 that 
there is an absence of long-term data, but disagree that long-term placebo-controlled RCTs 
provide the solution. There are serious ethical problems in extending placebo-controlled 
RCTs into the longer-term where there is evidence of strong benefit.  In our view a more 
appropriate design would be “randomized discontinuation trials” as proposed in the NICE 
guideline1. These, along with longer-term safety studies, are now a requirement of the 
regulatory development programme of the European Medicines Agency for new ADHD 
medications.  
Assessment of study quality. Storebø et al.4 adopted the GRADE approach 
(http://handbook.cochrane.org/chapter_12/12_2_1_the_grade_approach.htm), which includes 
the Cochrane risk of bias (RoB) tool 
(http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm. 
Using GRADE with regards to the main outcome (teacher-rated ADHD symptoms), they 
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downgraded the quality of evidence by one point for inconsistency of effects (heterogeneity) 
and by two points for risk of bias. Both these decisions are questionable. In relation to 
heterogeneity, I2 for the meta-analysis of the primary outcome was 37%. The Cochrane 
Handbook suggests that heterogeneity up to 40% “might not be important”. This 
downgrading is not appropriate, especially considering that exclusion of the MTA study 
reduces heterogeneity to 25%.  
With regard to the RoB assessment, we identified two major issues. First, Storebø et 
al.4 added an additional domain, ‘vested interests’, which is not included in the current 
Cochrane RoB. The authors support their choice, citing a single work9 and the Assessing the 
Methodological Quality of Systematic Reviews approach (AMSTAR) (http://amstar.ca/).  
While there remains controversy over the best method to account for vested interests,10 11 the 
Cochrane Handbook suggests that it should be reported in the ‘characteristics of included 
studies’ table rather than in the RoB.  Moreover, it is unclear how Storebø and colleagues4 
handled the assessment of vested interests in specific cases. They defined a trial as being at 
“high risk of bias” when it was “funded by parties that might have had a conflict of interest 
(e.g., a manufacturer of methylphenidate) or where potential conflicts of interest were 
reported by trial authors”. However there appears to be no further specification, for example, 
the number or role of authors with supposed conflict of interest, the time frame of the 
putative conflicts or the type of industry support that would lead to a study being rated as 
biased. This may partially explain why this domain was inconsistently rated across the 
included trials (see Appendix, Table 1 for examples). In a BMJ online reply to the concerns 
of others about their use of this domain, the authors stated “There were no trials with only the 
'vested interest bias' domain assessed as 'unclear risk of bias' or 'high risk of bias’.” This is 
incorrect; there are actually seven studies in which this was the only RoB domain rated as 
unclear or high (see Appendix, Table 2).  
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Storebø et al.4  rated studies as being at high risk of bias if any domain (including 
their additional domain of vested interests) was rated as high or unclear. This approach is 
problematic because domains were rated as unclear due to lack of detailed information. 
However, there is no evidence that the authors routinely attempted to contact authors for 
clarification regarding RoB domains (including vested interest) rated as ‘unclear’ (see 
Appendix, page 3), although they did contact some authors for missing quantitative data. For 
example, in the study by Ashare et al.12 five RoB domains were rated as “unclear” due to a 
lack of information. Whilst Storebø et al.4 wrote that they contacted the authors for 
quantitative data, there is no evidence they requested RoB information. 
Storebø et al.4 argue that the low quality of studies (their assessment) casts doubt on 
the accuracy of effect sizes. A more scientific approach is to test their opinion with the 
available data on RoB and study quality. The authors compared RCTs at high versus low risk 
of all bias (their ratings) and found no significant difference in effect size (χ21=2.43, p=.12). 
Unfortunately, this finding is not included in their adjunct publications in the BMJ13 and 
JAMA14. 
Storebø et al.4 went on to suggest that even those studies where no item of the RoB 
was rated as high/unclear were likely to be biased, due to unblinding. They assumed that 
“people in the trial might know which treatments the children were taking” because of 
adverse effects associated with MPH. We deem this unlikely, at least with their primary 
outcome ratings from teachers. The most common adverse effects reported are sleep 
difficulties and appetite reduction. There is no evidence to support the claim that teachers 
would be aware of these symptoms in their pupils and this is not our clinical experience.  
 Serious adverse effects (SAEs) of MPH. The authors used data from nine parallel 
group trials involving 1,532 participants to explore SAEs. They reported a risk ratio of 0.98 
(95% CIs 0.44, 2.22), which did not change significantly with the inclusion of 1,712 
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participants from both arms of crossover trials (RR=1.50, 95% CIs 0.34, 7.71). They point to 
the findings from trial sequential analysis to show that the sample size is underpowered to 
detect SAEs of the frequency reported for MPH versus placebo. It is common knowledge that 
short-term RCTs are neither intended nor powered to evaluate rare adverse effects and long-
term safety. While this is a limitation of the available evidence, a more balanced 
interpretation of the current evidence is that SAEs due to MPH are rare in clinical trials. The 
vast majority of published observational studies also suggest that SAEs are rare in clinical 
practice and that the causal associations between these SAE and MPH (rather than to ADHD 
itself or other associated conditions) remain to be confirmed. 
Effect sizes and clinical effectiveness. In a comparison of meta-analyses for common 
treatments in medicine and psychiatry, Leucht et al.16 showed that the effect size for MPH 
compares favourably both with medications for other psychiatric conditions and also with 
other commonly used interventions in medical conditions. Notable were the moderate effects 
for corticosteroids in asthma (0.54) and antihypertensives in high blood pressure (0.54, 0.56 
for systolic and diastolic blood pressure), with a small effect of the latter for long-term 
cardiovascular outcome/mortality (0.11). In this context, the efficacy of MPH should be 
viewed favourably.  
A further difficulty with the interpretation of Storebø et al.4  is their translation of 
group-based effect sizes into mean levels of symptom reduction in an attempt to quantify 
individual improvement. This is an uninformative and inaccurate measure of individual 
response as it fails to account for baseline symptom severity and the proportion of treated 
individuals showing clinical benefit, due to inter-individual variability in response. Clinical 
impact for individuals is better described using the number needed to treat and to harm 
metrics, which were not presented. 
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In addition to these major conceptual and methodological issues, we checked Storebø 
et al.’s4 primary analysis of teacher-reported ADHD symptoms. Among the 19 studies 
reported (three of which we have argued should not have been included), compared to the 
published data, we found errors in the imputation of data and/or sample size in seven. These 
errors included a systematic doubling of the sample sizes for all crossover trials (by counting 
each arm as if they were independent) (Appendix, Table 3). Because these errors occurred in 
both directions, correction of the data had little impact on the aggregate SMD for this 
outcome. Our limited check raises concerns about the accuracy of the other quantitative 
findings and the overall quality and conduct of the review.  
In summary, we think that the analysis undertaken by Storebø et al.4 is flawed and the 
conclusions misplaced. The additional benefits of MPH in improving both general behaviour 
(SMD -0.68, 95% CIs -0.78, -0.60) and quality of life (SMD 0.61, 95% CIs 0.48, 0.80) 
further support the value of MPH for youth with ADHD. We are therefore perplexed why the 
authors refer to their own findings as “apparent effects” (our emphasis). While we agree that 
some of the trials included in this review are at risk of bias, this aspect of the evidence has not 
been assessed well. This has led to an overly negative interpretation of the evidence.  
It is unfortunate that the authors focus on problems with the quality of the evidence 
when their own analyses do not support a significant impact of study risk of bias on the effect 
of MPH. Reviewers are becoming more transparent about the methods to assess study design 
and data analysis. However, it is still much more difficult to objectively address the 
introduction of bias through interpretation that appears in the discussion section of a paper. 
In this case, we believe that the interpretation given by Storebø et al.4 is not warranted, given 
their errors and deviations from currently recommended methods.  
The beneficial effects of MPH (and other medications for ADHD) need to be placed 
in the context of other, non-pharmacological, interventions for ADHD. In a systematic review 
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and meta-analysis of RCTs, we found a relative lack of efficacy on blinded outcomes in 
reducing ADHD symptoms for many of these.17-20 Where these interventions lead to 
beneficial reductions in ADHD symptoms, the magnitude of these effects is considerably less 
than that reported for MPH, and indeed other stimulant and non-stimulant ADHD 
medications. We therefore believe that there is continued support for the use of MPH as an 
effective and safe treatment for ADHD.  
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